Compare ACAD & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | INDV |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2000 | 2014 |
| Metric | ACAD | INDV |
|---|---|---|
| Price | $21.74 | $30.54 |
| Analyst Decision | Buy | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $30.55 | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 3.0M |
| Earning Date | 05-06-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.12 | ★ 8100.00 |
| EPS | ★ 2.30 | 1.64 |
| Revenue | $726,437,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | $18.90 | N/A |
| Revenue Next Year | $11.62 | N/A |
| P/E Ratio | ★ $9.81 | $19.68 |
| Revenue Growth | ★ 40.45 | 4.29 |
| 52 Week Low | $14.08 | $8.69 |
| 52 Week High | $28.35 | $38.00 |
| Indicator | ACAD | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 47.42 |
| Support Level | $21.51 | $29.71 |
| Resistance Level | $22.03 | $35.75 |
| Average True Range (ATR) | 0.72 | 1.18 |
| MACD | 0.19 | 0.31 |
| Stochastic Oscillator | 51.38 | 57.87 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).